To the Editor We would like to highlight important methodological limitations to the case-control study by Singh et al,1 in which the authors investigated whether an association might exist between acute pancreatitis and use of glucagon-like peptide 1 (GLP-1)–based therapies in patients with type 2 diabetes mellitus using an insurance claims database.
Brodovicz KG, Engel SS, Thornberry NA. Glucagon-like Peptide 1–Based Drugs and Pancreatic Safety. JAMA Intern Med. 2013;173(19):1842-1843. doi:10.1001/jamainternmed.2013.8138